By vgreene, 22 March, 2020 Other drugs (eg, investigational antivirals, immunotherapeutic, host-directed therapies) under investigation or being considered for trials of pre- and post-exposure prophylaxis or tx of COVID-19
By vgreene, 22 March, 2020 Remdesivir (investigational IV drug w/ broad antiviral activity, incl SARS-CoV-2): Four current options to obtain remdesivir:
By vgreene, 22 March, 2020 In areas w/o clinical trials, pts have been treated on an uncontrolled compassionate use basis; currently not accepting new requests pending transition to an expanded access program. More info available at manufacturer site.
By vgreene, 22 March, 2020 Two phase 3 randomized open label trials of remdesivir (5 vs 10 days vs standard care) enrolling pts ≥18 yo w/ COVID-19, radiographic evidence of pneumonia, & O2 sat ≤94% on room air (severe dz: trial) or >94% on room air (moderate dz: trial). Exclusions:
By vgreene, 22 March, 2020 NIH adaptive trial for COVID-19 pts w/ pneumonia & hypoxia; enrolling pts ≥18 yo w/ O2 sat ≤94% on room air or requiring supplemental O2/mechanical ventilation. Exclusions: ALT/AST >5X ULN, stage 4 CKD, or requires dialysis (eGFR
By vgreene, 22 March, 2020 Hydroxychloroquine currently under investigation in clinical trials for pre-exposure and post-exposure prophylaxis of SARS-CoV-2 and tx of mild, mod, severe COVID-19. See epocrates COVID-19 Drug Therapy Trial Updates decision tool or ClinicalTrials.gov